1. Home
  2. LCFY vs NVNO Comparison

LCFY vs NVNO Comparison

Compare LCFY & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

N/A

Current Price

$4.50

Market Cap

5.9M

Sector

N/A

ML Signal

N/A

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

N/A

Current Price

$12.02

Market Cap

6.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LCFY
NVNO
Founded
2009
1987
Country
Australia
United States
Employees
N/A
37
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
6.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LCFY
NVNO
Price
$4.50
$12.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.9K
10.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.30
52 Week High
$13.98
$12.85

Technical Indicators

Market Signals
Indicator
LCFY
NVNO
Relative Strength Index (RSI) 62.05 64.52
Support Level $3.92 $0.49
Resistance Level $4.81 $12.64
Average True Range (ATR) 0.29 1.19
MACD 0.00 -0.06
Stochastic Oscillator 79.17 78.55

Price Performance

Historical Comparison
LCFY
NVNO

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: